Advanced search
Publication Cover
Cancer Management and Research Volume 15, 2023 - Issue
Submit an article Journal homepage
150
Views
0
CrossRef citations to date
0
Altmetric
CASE REPORT

A Metastatic Pulmonary Sarcomatoid Carcinoma Patient Harboring KIF5B-RET Fusion Responds to First-Line Pralsetinib Treatment: A Case Report

Hao Qin1 Department of Respiratory and Critical Care Medicine, Shanghai Changhai Hospital, The First Affiliated Hospital of Second Military Medical University, Shanghai, People’s Republic of ChinaView further author information
,
Yuxiang Wan2 Department of Laboratory Diagnosis, Shanghai Changhai Hospital, The First Affiliated Hospital of Second Military Medical University, Shanghai, People’s Republic of ChinaView further author information
,
Yuchao Dong1 Department of Respiratory and Critical Care Medicine, Shanghai Changhai Hospital, The First Affiliated Hospital of Second Military Medical University, Shanghai, People’s Republic of ChinaCorrespondence[email protected] [email protected]
View further author information
&
Qinying Sun1 Department of Respiratory and Critical Care Medicine, Shanghai Changhai Hospital, The First Affiliated Hospital of Second Military Medical University, Shanghai, People’s Republic of ChinaView further author information
Pages 765-769 | Received 30 Mar 2023, Accepted 10 Jul 2023, Published online: 26 Jul 2023

References

  • Yendamuri S, Caty L, Pine M, et al. outcomes of sarcomatoid carcinoma of the lung: a surveillance, epidemiology, and end results database analysis. Surgery. 2012;152(3):397–402. doi:10.1016/j.surg.2012.05.007
  • Shum E, Stuart M, Borczuk A, Wang F, Cheng H, Halmos B. Recent advances in the management of pulmonary sarcomatoid carcinoma. Expert Rev Respir Med. 2016;10(4):407–416. doi:10.1586/17476348.2016.1157475
  • Vieira T, Girard N, Ung M, et al. Efficacy of first-line chemotherapy in patients with advanced lung sarcomatoid carcinoma. J Thorac Oncol. 2013;8(12):1574–1577. doi:10.1097/01.JTO.0000437008.00554.90
  • Schrock AB, Li SD, Frampton GM, et al. pulmonary sarcomatoid carcinomas commonly harbor either potentially targetable genomic alterations or high tumor mutational burden as observed by comprehensive genomic profiling. J Thorac Oncol. 2017;12(6):932–942. doi:10.1016/j.jtho.2017.03.005
  • Liang X, Li Q, Xu B, et al. Mutation landscape and tumor mutation burden analysis of Chinese patients with pulmonary sarcomatoid carcinomas. Int J Clin Oncol. 2019;24(9):1061–1068. doi:10.1007/s10147-019-01454-6
  • Qin J, Chen B, Li C, Yan J, Lu H. Genetic heterogeneity and predictive biomarker for pulmonary sarcomatoid carcinomas. Cancer Genet. 2021;250–251:12–19. doi:10.1016/j.cancergen.2020.11.004
  • Drilon A, Oxnard GR, Tan DSW, et al. Efficacy of Selpercatinib in RET Fusion–Positive Non–Small-Cell Lung Cancer. N Engl J Med. 2020;383(9):813–824. doi:10.1056/NEJMoa2005653
  • Gainor JF, Curigliano G, Kim DW, et al. Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, Phase 1/2 study. Lancet Oncol. 2021;22(7):959–969. doi:10.1016/S1470-2045(21)00247-3
  • Li AY, McCusker MG, Russo A, et al. RET fusions in solid tumors. Cancer Treat Rev. 2019;81:101911. doi:10.1016/j.ctrv.2019.101911
  • Takahashi M, Ritz J, Cooper GM. Activation of a novel human transforming gene, ret, by DNA rearrangement. Cell. 1985;42(2):581–588. doi:10.1016/0092-8674(85)90115-1
  • Santos C, Sanz-Pamplona R, Salazar R. RET-fusions: a novel paradigm in colorectal cancer. Ann Oncol. 2018;29(6):1340–1343. doi:10.1093/annonc/mdy132
  • Paratala BS, Chung JH, Williams CB, et al. RET rearrangements are actionable alterations in breast cancer. Nat Commun. 2018;9(1):4821. doi:10.1038/s41467-018-07341-4
  • Wu Y, Yan Z, Pan J, et al. Partial response to pralsetinib in an advanced pulmonary sarcomatoid carcinoma patient harboring a KIF5B-RET rearrangement: a case report. World J Surg Oncol. 2022;20(1):386. doi:10.1186/s12957-022-02848-z
  • Subbiah V, Gainor JF, Rahal R, et al. Precision targeted therapy with BLU-667 for RET-driven cancers. Cancer Discov. 2018;8(7):836–849. doi:10.1158/2159-8290.CD-18-0338
  • Illini O, Hochmair MJ, Fabikan H, et al. Selpercatinib in RET fusion-positive non-small-cell lung cancer (SIREN): a retrospective analysis of patients treated through an access program. Ther Adv Med Oncol. 2021;13:17588359211019675. doi:10.1177/17588359211019675
  • Subbiah V, Hu MI, Wirth LJ, et al. Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, Phase 1/2 study. Lancet Diabetes Endocrinol. 2021;9(8):491–501. doi:10.1016/S2213-8587(21)00120-0
  • Griesinger F, Curigliano G, Thomas M, et al. Safety and efficacy of pralsetinib in RET fusion-positive non-small-cell lung cancer including as first-line therapy: update from the ARROW trial. Ann Oncol. 2022;33(11):1168–1178. doi:10.1016/j.annonc.2022.08.002
  • Subbiah V, Cassier PA, Siena S, et al. Pan-cancer efficacy of pralsetinib in patients with RET fusion-positive solid tumors from the phase 1/2 ARROW trial. Nat Med. 2022;28(8):1640–1645. doi:10.1038/s41591-022-01931-y

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.